Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS. Br J Haematol 2025 Sep;207(3):1011-1018
Date
07/23/2025Pubmed ID
40693472Pubmed Central ID
PMC12705125DOI
10.1111/bjh.70020Scopus ID
2-s2.0-105011357932 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a pivotal part of the treatment algorithm for large B-cell lymphoma (LBCL) in the second- and third-line settings based on numerous clinical trials. However, these studies included very few patients with a diagnosis of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) and it is unclear if outcomes are similar to those observed with more common LBCL histologies. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we identified 111 HGBCL-NOS patients who received CAR-T therapy. The cytokine release syndrome (CRS) rate was 74% (7.7% grade 3+), median onset was 4 days (1-17) and immune effector cell-associated neurotoxicity syndrome rate was 45.2% (22.6% grade 3+), median onset was 7 days (1-17). At 2 years post-CAR-T infusion, the probability of overall survival and progression-free survival were 41.6% and 28.7% respectively. The 2-year non-relapse mortality and relapse/progression were 3.1% (95% confidence interval [CI]: 0.6-7.6) and 68.1% (95% CI: 57.9-77.6) respectively. Our analysis illustrates that patients with HGBCL-NOS represent a particularly difficult group to treat, even with CAR-T therapy. We observed that one third of patients achieved a durable response; however, the overall results were less favourable, with lower overall response rate, overall survival and progression-free survival as compared to published reports on LBCL.
Author List
Hossain NM, Ahn KW, Patel J, Lian Q, Bilal Abid M, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AFAuthors
Kwang Woo Ahn PhD Director, Professor in the Data Science Institute department at Medical College of WisconsinMehdi Hamadani MBBS Professor in the Medicine department at Medical College of Wisconsin
Jinal K. Patel Biostatistician II in the Center for International Blood and Marrow Transplant Research department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Female
Humans
Immunotherapy, Adoptive
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Registries
Young Adult









